Swiss drug development company Relief Therapeutics Holdings SA (Relief Therapeutics)(SWX:RLF) said on 23 September 2020 that along with its US partner NeuroRx, it has asked the US Food and Drug Administration for emergency approval for a drug it aims to repurpose against COVID-19, Reuters news agency reported on Wednesday.
Citing a 51-person study, Relief Therapeutics said in a statement: "Patients treated with RLF-100 demonstrated a three-fold advantage in survival, recovery from respiratory failure and other parameters indicative of meaningful clinical improvement."
The company added that the request, if granted, would make the drug, previously used against conditions including erectile dysfunction, available to those in intensive care who have exhausted all approved treatments.
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA